Beam Therapeutics Inc (BEAM)

May 20, 2026, 2:05 PM EDT - 9 days ago

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

May 20, 2026, 10:30 AM EDT - 10 days ago

Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-18T20:35:07.000Z - 11 days ago

Beam Therapeutics presents Phase 1/2 data for BEAM-302

May 18, 2026, 4:00 PM EDT - 11 days ago

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

May 13, 2026, 11:49 AM EDT - 16 days ago

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

May 13, 2026, 7:00 AM EDT - 17 days ago

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

2026-05-13T10:37:27.000Z - 17 days ago

Beam Therapeutics price target lowered to $39 from $40 at Bernstein

May 12, 2026, 9:30 AM EDT - 18 days ago

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

2026-05-07T13:39:55.000Z - 23 days ago

Beam Therapeutics reports Q1 EPS (91c), consensus ($1.01)

May 7, 2026, 7:00 AM EDT - 23 days ago

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

May 7, 2026, 7:00 AM EDT - 23 days ago

Beam Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 23 days ago

Beam Therapeutics Quarterly report: Q1 2026

2026-04-27T16:07:48.000Z - 4 weeks ago

Beam Therapeutics rises 10.7%

2026-04-27T14:34:03.000Z - 4 weeks ago

Beam Therapeutics rises 10.8%

Apr 27, 2026, 7:06 AM EDT - 4 weeks ago

3 Biotech Stocks That Could Benefit from the Patent Cliff

CRSP NTLA

Apr 17, 2026, 8:00 AM EDT - 6 weeks ago

Beam Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 6 weeks ago

Beam Therapeutics Proxy statement: Proxy filing

2026-04-01T21:20:15.000Z - 2 months ago

Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial

Apr 1, 2026, 5:12 PM EDT - 2 months ago

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

2026-03-26T10:25:10.000Z - 2 months ago

Beam Therapeutics price target raised to $68 from $64 at Citi

2026-03-25T16:55:13.000Z - 2 months ago

Clear Street sees buying opportunity for Beam Therapeutics after study update

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Beam Therapeutics Transcript: Study result

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Beam Therapeutics Press release: Study result

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Beam Therapeutics Slides: Study result

2026-03-25T11:27:05.000Z - 2 months ago

Beam Therapeutics announces safety, efficacy data from BEAM-302 trial

Mar 25, 2026, 7:00 AM EDT - 2 months ago

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

2026-02-25T14:29:20.000Z - 3 months ago

Beam Therapeutics price target raised to $26 from $22 at RBC Capital

2026-02-25T13:38:56.000Z - 3 months ago

Beam Therapeutics price target raised to $65 from $57 at Wedbush

2026-02-25T11:54:44.000Z - 3 months ago

Beam Therapeutics price target raised to $75 from $74 at Canaccord

2026-02-24T16:35:13.000Z - 3 months ago

Beam Therapeutics price target raised to $47 from $45 at BofA

PFE

Feb 24, 2026, 8:00 AM EST - 3 months ago

Beam Therapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:00 AM EST - 3 months ago

Beam Therapeutics Annual report: Q4 2025

Feb 24, 2026, 8:00 AM EST - 3 months ago

Beam Therapeutics Earnings release: Q4 2025

2026-02-24T12:36:56.000Z - 3 months ago

Beam Therapeutics announces $500M financing facility

2026-02-24T12:11:47.000Z - 3 months ago

Beam Therapeutics reports Q4 EPS $2.33 vs ($1.09) last year

Feb 24, 2026, 7:01 AM EST - 3 months ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Feb 24, 2026, 7:00 AM EST - 3 months ago

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Feb 23, 2026, 4:00 PM EST - 3 months ago

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

2026-02-20T11:56:35.000Z - 3 months ago

Beam Therapeutics initiated with a Buy at Canaccord

Jan 13, 2026, 8:15 PM EST - 4 months ago

Beam Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:15 PM EST - 4 months ago

Beam Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 5:00 PM EST - 4 months ago

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

Dec 18, 2025, 4:01 PM EST - 5 months ago

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 6, 2025, 8:00 AM EST - 6 months ago

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Nov 19, 2025, 10:30 AM EST - 6 months ago

Beam Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Nov 4, 2025, 4:00 PM EST - 7 months ago

Beam Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 7 months ago

Beam Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 7:00 AM EST - 7 months ago

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 3, 2025, 9:00 AM EST - 7 months ago

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Sep 8, 2025, 10:30 AM EDT - 9 months ago

Beam Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 1:30 PM EDT - 9 months ago

Beam Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 4:00 PM EDT - 9 months ago

Beam Therapeutics Transcript: Citi's Biopharma Back to School Conference

Aug 25, 2025, 7:00 AM EDT - 9 months ago

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Beam Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Beam Therapeutics Quarterly report: Q2 2025

Jun 13, 2025, 4:00 PM EDT - 1 year ago

Beam Therapeutics Transcript: The European Hematology Association Congress 2025

Jun 13, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

May 29, 2025, 4:01 PM EDT - 1 year ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 20, 2025, 11:00 AM EDT - 1 year ago

Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 14, 2025, 9:30 AM EDT - 1 year ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 13, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025, 4:01 PM EDT - 1 year ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 6, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 6, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Quarterly report: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Earnings release: Q1 2025

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Proxy statement: Proxy Filing

Apr 5, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Mar 31, 2025, 2:25 PM EDT - 1 year ago

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

MRNA

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Mar 11, 2025, 3:30 PM EDT - 1 year ago

Beam Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 10, 2025, 1:40 PM EDT - 1 year ago

Beam Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Transcript: Study Update

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Press release: Study Update

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Beam Therapeutics Slides: Study Update

Mar 10, 2025, 6:01 AM EDT - 1 year ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:00 AM EDT - 1 year ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Mar 3, 2025, 1:50 PM EST - 1 year ago

Beam Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Feb 25, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Annual report: Q4 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Earnings release: Q4 2024

Feb 24, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Feb 6, 2025, 2:30 PM EST - 1 year ago

Beam Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 13, 2025, 4:30 PM EST - 1 year ago

Beam Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Dec 8, 2024, 11:00 PM EST - 1 year ago

Beam Therapeutics Transcript: Status Update

Dec 8, 2024, 11:00 PM EST - 1 year ago

Beam Therapeutics Press release: Status Update

Dec 8, 2024, 11:00 PM EST - 1 year ago

Beam Therapeutics Slides: Status Update

Dec 8, 2024, 1:45 PM EST - 1 year ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Dec 7, 2024, 11:30 AM EST - 1 year ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Dec 6, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Dec 4, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Nov 19, 2024, 5:00 AM EST - 1 year ago

Beam Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 4:01 PM EST - 1 year ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Nov 5, 2024, 8:30 AM EST - 1 year ago

Beam Therapeutics Earnings Call Transcript: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Beam Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Beam Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Beam Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Beam Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Jul 15, 2024, 6:30 AM EDT - 2 years ago

Beam Therapeutics Announces Transition of Chief Financial Officer

Jun 26, 2024, 6:30 AM EDT - 2 years ago

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 14, 2024, 3:00 AM EDT - 2 years ago

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

Jun 6, 2024, 1:30 PM EDT - 2 years ago

Beam Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 6:30 AM EDT - 2 years ago

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference